Nausea Post Chemotherapy Clinical Trial
Official title:
Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer
This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetogenic chemotherapy.
The population of the study is women diagnosed with breast cancer, who will start chemotherapy (Doxorubicine and Cyclophosfamide). We will evaluate the control of nausea and vomiting in the first cycle of chemotherapy, utilizing Netupitant (300mg) + palonosetron (0,56mg) in day 1 and Olanzapine 5mg starting on Day 0, given once a day for five days. The primary endpoint of this study is complete response rate (no nausea, no emesis no use of rescue medication). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03478605 -
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
|
Phase 2 | |
Completed |
NCT03572829 -
Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
|
Phase 2 | |
Completed |
NCT01504711 -
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
|
N/A | |
Recruiting |
NCT04141514 -
Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy
|
N/A | |
Not yet recruiting |
NCT05272865 -
Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03996863 -
Prevention of Unmitigated Chemotherapy-induced Emesis
|
N/A |